Iovance Biotherapeutics (IOVA) AGM 2024 summary

Opening remarks and agenda

• Quorum confirmed and meeting duly convened; polls opened for online voting with technical support available.

• Proxy statement and meeting notice made available on May 9, 2024, for shareholders of record as of April 17, 2024.

• Q&A session scheduled after business presentation, with questions submitted via the online portal.

Shareholder proposals

• Election of directors to serve until the 2025 annual meeting.

• Advisory approval of executive compensation.

• Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2024.

• Amendment to 2018 Equity Incentive Plan to increase authorized shares from 29.7M to 36.7M.

• Amendment to 2020 Employee Stock Purchase Plan to increase authorized shares from 1.4M to 1.9M.

Overview of voting outcomes

• All director nominees elected to serve until 2025.

• Executive compensation approved.

• Ernst & Young LLP ratified as auditor.

• Amendments to both the 2018 Equity Incentive Plan and 2020 Employee Stock Purchase Plan approved.

• All proposals passed; final results to be filed in Form 8-K.